Clinical Trial Detail

NCT ID NCT02551055
Title MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements no
Sponsors Millennium Pharmaceuticals, Inc.
Indications

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma

Advanced Solid Tumor

Therapies

Docetaxel

Paclitaxel

Alisertib

TAK-659

MLN1117

Age Groups: adult

No variant requirements are available.